Compare UiPath Inc (PATH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Repligen Corporation Common Stock — how do they compare? UiPath Inc trades at $12.97 (market cap $6.91B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Repligen Corporation Common Stock for 0 Days on average.
| PATH | RGEN | |
|---|---|---|
Market Cap | $6.91B | $11.14B |
Volume | 26,239,123 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $19.29 | $194.57 |
52-Week Low | $9.38 | $102.87 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $5.70B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.06, down 1.95% on the day, with a bullish technical signal from moving averages but neutral oscillators. Revenue growth is robust, increasing from $1.3B in 2024 to $1.43B in 2025, with a projected net profit of $362M in 2026. Recent news highlights expanded AI partnerships and raised guidance, though the stock faces near-term volatility.
The outlook is cautiously optimistic, with a consensus price target of $15.13 offering potential upside. Key opportunities include strong enterprise demand and AI monetization, while risks involve competitive pressures and execution challenges in achieving profitability targets. Analyst sentiment is mixed, with a majority hold rating.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
